Sugi Predict

Sugi Predict / Compounds / SCHEMBL1998421

SCHEMBL1998421

SCHEMBL1998421

COC(=O)c1ccnc2cc(Br)ccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ TSHR P16473 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ NR4A2 P43354 1/20 0.48
▸ GAK O14976 1/20 0.47
▸ PSMD14 O00487 1/20 0.46
▸ ALK Q9UM73 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ SLC22A12 Q96S37 2/20 0.43
▸ CHEK1 O14757 1/20 0.43
▸ PREP P48147 1/20 0.43
▸ KDM4E B2RXH2 4/20 0.42
▸ MAPT P10636 1/20 0.42
▸ ABCG2 Q9UNQ0 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30717956 1.00 L3MBTL1 (0.51) L3MBTL1TSHRHTTNR4A2GAK
SCHEMBL29680913 0.88 L3MBTL1 (0.62) L3MBTL1TSHRHTTNR4A2GAK
SCHEMBL20074656 0.88 L3MBTL1 (0.62) L3MBTL1TSHRHTTNR4A2GAK
Hydrochloric Acid SCHEMBL29090984 0.87 L3MBTL1 (0.60) L3MBTL1TSHRHTTNR4A2GAK
Hydrochloric Acid SCHEMBL29681190 0.87 L3MBTL1 (0.60) L3MBTL1TSHRHTTNR4A2GAK
SCHEMBL31053285 0.84 ALDH1A1 (0.55) TSHRKDM4EMAPTLMNAALDH1A1
SCHEMBL19643044 0.83 NR4A2 (0.50) NR4A2PSMD14PREPKDM4EMAPT
SCHEMBL19643450 0.83 CA12 (0.51) HTTPSMD14KDM4EMAPTLMNA
SCHEMBL31153486 0.82 GAK (0.47) L3MBTL1GAKPSMD14KDM4ELMNA
SCHEMBL28544101 0.82 GAA (0.51) TSHRHTTPSMD14HSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112500341-B Synthesis method of 7-hydroxyquinoline-4-carboxylic acid 苏州康润医药有限公司 2022-04-12 — — CN claimed
CN-112500341-A Synthesis method of 7-hydroxyquinoline-4-carboxylic acid 苏州康润医药有限公司 2021-03-16 — — CN claimed
EP-4543869-B1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2026-05-27 — — EP disclosed
WO-2025106939-A1 CONJUGATES TARGETING FIBROBLAST ACTIVATION PROTEIN AND USES THEREOF Praxis Biotech LLC (US) 2025-05-22 — — WO disclosed
CN-119562947-A N- (2- (3-cyano-2-azabicyclo [3.1.0] hex-2-yl) -2-oxoethyl) -quinoline-4-carboxamide 阿斯利康(瑞典)有限公司 2025-03-04 — — CN disclosed
WO-2023247488-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)- QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-12-28 — — WO disclosed
US-20230406840-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES ASTRAZENECA AB (SE) 2023-12-21 — — US disclosed
CN-112500341-B Synthesis method of 7-hydroxyquinoline-4-carboxylic acid 苏州康润医药有限公司 2022-04-12 — — CN disclosed
CN-112500341-B Synthesis method of 7-hydroxyquinoline-4-carboxylic acid 苏州康润医药有限公司 2022-04-12 — — CN disclosed
WO-2022068772-A1 BENZIMIDAZOLE DERIVATIVE, AND PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF 深圳信立泰药业股份有限公司 2022-04-07 — — WO disclosed
CN-112500341-A Synthesis method of 7-hydroxyquinoline-4-carboxylic acid 苏州康润医药有限公司 2021-03-16 — — CN disclosed
WO-2008051942-A2 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-02 — — WO disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
US-6410529-B1 DIETETICS; NON-INSULIN DEPENDENT DIABETES; SLEEP DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-06-25 — — US disclosed
EP-1003737-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 2000-05-31 — — EP disclosed
EP-0983244-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS SMITHKLINE BEECHAM PLC (GB) 2000-03-08 — — EP disclosed
WO-1999009024-A1 PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS HFGAN72 ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1999-02-25 — — WO disclosed
WO-1998050364-A1 TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS SMITHKLINE BEECHAM PLC (GB) 1998-11-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS NR1H4, NR1H3, NR1H2 L3MBTL1 4859/4885TSHR 486/4885HTT 4696/4885
US-20230406840-A1 N-(2-(3-CYANO-2-AZABICYCLO[3.1.0]HEXAN-2-YL)-2-OXOETHYL)QUINOLINE-4-CARBOXAMIDES FAP, PREP, HEXA L3MBTL1 4409/4885TSHR 2160/4885HTT 2996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.